The deal, which covers around 76,000 cases, marks a significant development in one of the longest-running product liability disputes in US corporate history. However, the agreement will come into effect only if at least 95% of claimants approve the settlement.

Settlement aims to resolve long-running litigation

The proposed settlement is expected to resolve nearly all existing ovarian cancer claims filed against Johnson & Johnson. The litigation has spanned more than a decade, involving multiple jury trials, appeals, and several legal strategies by the company to limit its liability.

Despite agreeing to the payout, the company reiterated that it does not admit any wrongdoing. It has consistently maintained that its talc-based products are safe and free from asbestos.

Erik Haas, Vice President of Litigation at Johnson & Johnson, stated that while the company believes it could have prevailed in court, the settlement allows it to move forward and focus on its core healthcare mission.

Payment timeline and potential increase in payout

Under the current proposal, Johnson & Johnson plans to pay approximately $3 billion in 2027, with the remaining amount scheduled for 2028.

However, the final payout could exceed $7 billion (over ₹57,000 crore), depending on the number of claimants who opt into the settlement. Legal representatives for the plaintiffs indicated that higher participation levels could push the overall compensation figure upwards.

If approved, compensation is expected to be distributed within about 18 months, making the process faster compared to previous legal approaches.

Allegations over talc products and cancer risk

The lawsuits allege that prolonged use of Johnson & Johnson's talc-based baby powder and similar products led to ovarian cancer in thousands of women. Many plaintiffs also claimed that the talc contained asbestos, a known carcinogen.

Johnson & Johnson has repeatedly denied these allegations, citing scientific studies and regulatory findings that support the safety of its products.

The company discontinued the sale of talc-based Johnson's Baby Powder in the United States in 2020 and replaced it with a cornstarch-based alternative.

Bankruptcy strategy and legal setbacks

In earlier attempts to manage the litigation, Johnson & Johnson adopted the controversial "Texas two-step" strategy. This involved creating a subsidiary to absorb talc-related liabilities and then filing for bankruptcy protection.

However, courts rejected this approach multiple times, dismissing three separate bankruptcy filings and allowing lawsuits to proceed through the traditional legal system.

The current settlement differs from those earlier attempts, as it applies only to existing claims and does not prevent future lawsuits from being filed.

What happens next

The proposed agreement will now be circulated among eligible claimants for approval. If at least 95% agree to the terms, the settlement will proceed, potentially bringing closure to the majority of ongoing cases.

If the required approval threshold is not met, Johnson & Johnson could face continued litigation across multiple US courts, prolonging a legal battle that has already lasted more than ten years.

Conclusion

The $5.5 billion settlement proposal represents a major step towards resolving a complex and high-profile legal dispute involving Johnson & Johnson's talc products. While the company continues to deny liability, the agreement offers a pathway to compensate thousands of claimants and reduce prolonged legal uncertainty.

The final outcome now depends on claimant approval, which will determine whether this long-standing case reaches a conclusion or returns to the courtroom.